ArticleBlood cancer journal2023

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

P J Hengeveld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.